Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis.

Armstrong-Buisseret, Lindsay, Brittain, Clare, David, Miruna, Dean, Gillian, Griffiths, Frances, Hepburn, Trish, Jackson, Louise, Kai, Joe, Montgomery, Alan, Roberts, Tracy, Thandi, Sukhwinder and Ross, Jonathan D C (2019) Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials, 20 (1). p. 648. ISSN 1745-6215.

[img]
Preview
Text (PDF File Format)
Metronidazole versus lactic acid for treating bacterial vaginosis VITA.pdf
Available under License Creative Commons Attribution 4.0.

Download (1MB) | Preview
Official URL: https://trialsjournal.biomedcentral.com/articles/1...

Abstract

BACKGROUND

Bacterial vaginosis (BV) affects 30-50% of women at some time in their lives and is an embarrassing and distressing condition which can be associated with potentially serious comorbidities. Current antibiotic treatments such as metronidazole are effective but can result in side effects, and recurrence is common. This trial aims to investigate whether lactic acid gel is clinically effective and cost effective in the treatment of recurrent BV compared with metronidazole.

METHODS

VITA is an open-label, multicentre, parallel group randomised controlled trial for women with a clinical diagnosis of BV and at least one previous BV episode in the past 2 years. Participants will be randomised 1:1 to intravaginal lactic acid gel 5 ml once daily for 7 days or oral metronidazole tablets 400 mg twice daily for 7 days. All participants will be followed up for 6 months to assess health status and healthcare costs. A subgroup will be interviewed to further explore adherence, tolerability and acceptability of treatment. The estimated sample size is 1900 participants to detect a 6% absolute increase in response rate to 86% in those receiving lactic acid gel. The primary outcome is participant-reported resolution of BV at Week 2.

DISCUSSION

Results from this trial will help inform UK treatment guidelines for BV and may provide an alternative effective treatment for recurrent episodes of this condition which avoids repeated exposure to antibiotics.

TRIAL REGISTRATION

ISRCTN, ISRCTN14161293. Registered on 8 September 2017.

Item Type: Article
Subjects: QW Microbiology. Immunology
WP Gynaecology. Women’s health
Divisions: Womens and Childrens
Related URLs:
Depositing User: Jennifer Manders
Date Deposited: 12 Dec 2019 13:27
Last Modified: 12 Dec 2019 13:27
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2680

Actions (login required)

View Item View Item